BAT-26, Microsatellite Instability (MSI) for Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
| BAT-26, Microsatellite Instability (MSI) for Hereditary Nonpolyposis Colorectal Cancer (HNPCC) | | | |
| Number | | 511253 |
| CPT | | 83891; 83892; 83898; 83904; 83907; 83909 (x2); 83912; 83914 (x2) |
| Related Information | | Microsatellite Instability |
| Synonyms | | HNPCC ; MSI ; PreGen-26™, Microsatellite Instability for Hereditary Nonpolyposis Colorectal Cancer |
| Special Instructions | | PreGen-26™ samples cannot be shipped via IARA regulated air carriers. They must be transported via airborne, federal express, other non-IARA air carriers, or by ground, as appropriate. |
| Specimen | | Stool |
| Volume | | Whole stool (one entire bowel movement is required) |
| Container | | PreGen-26™ specimen collection and transport materials (obtain No 3164 through LabCorp branch locations) |
| Collection | | Specimen should be collected and shipped Monday through Thursday using only the PreGen-26™ specimen collection instructions and transport materials. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested. |
| Storage Instructions | | Specimen should be refrigerated or stored frozen. Follow instructions carefully and transport only in a PreGen-26™ specimen collection and transport box. |
| Causes for Rejection | | Specimen received at room temperature; specimen on outside of container; improper labeling; quantity not sufficient for analysis |
| Use | | As an adjunct to colonoscopy for monitoring patients with hereditary nonpolyposis colorectal cancer (HNPCC) for development of cancer; used in conjunction with other tests, such as colonoscopy, for individuals with a strong family history of colorectal cancers or HNPCC-related cancers; an adjunct to colonoscopy for monitoring family members of patients with known or suspected HNPCC; monitor HNPCC patients who are noncompliant with cancer screening recommendations |
| Limitations | | While the vast majority (approximately 90%) of colorectal cancers associated with HNPCC are associated with mutated BAT-26, a certain percentage of colorectal cancer in these patients will not be detected. This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients. |
| Methodology | | Polymerase chain reaction (PCR) detection of microsatellite instability |
| Additional Information | | PreGen™ is a trademark of the exact Sciences Corporation. This is a molecular genetic test designed to detect the presence of cancer, especially in those patients who are predisposed to HNPCC. Cells from the colonic epithelium are shed into the colon each day and carried out of the body in stool. The BAT-26 assay technology involves the isolation of human DNA in stool and the detection of microsatellite instability usually associated with HNPCC and other cancers. PreGen-26™ identifies alterations in the BAT-26 mononucleotide marker, believed to be the most frequent alteration found in tissue in HNPCC. BAT-26 microsatellite instability is present in as many as 90% of the colorectal cancers that occur in patients with HNPCC. PreGen-26™ results can help to determine which patients are likely to have the presence of cancer with BAT-26 MSI. |
| References | | Aaltonen LA, Salovaara R, Kristo P, et al, “Incidence of Hereditary Nonpolyposis Colorectal Cancer and the Feasibility of Molecular Screening for the Disease,” N Engl J Med, 1998, 338(21):1481-7. Ahlquist DA, Skoletsky JE, Boynton KA, et al, “Colorectal Cancer Screening by Detection of Altered Human DNA in Stool: Feasibility of a Multitarget Assay Panel,” Gastroenterology, 2000, 119(5):1219-27. Dong SM, Traverso G, Johnson C, et al, “Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets,” J Natl Cancer Inst, 2001, 93(11):858-65. |
|